zonisamide has been researched along with Parkinsonian Disorders in 10 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No unexpected neurological or psychiatric adverse events occurred, and no adverse events increased in incidence in the open-label period." | 3.11 | Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial. ( Hasegawa, K; Kajiwara, R; Kosaka, K; Murata, M; Odawara, T; Tagawa, M; Takeuchi, H, 2022) |
| " Other outcomes included the changes in Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory-10 (NPI-10) scores, and the incidence of adverse events." | 3.01 | Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials. ( Hasegawa, K; Kochi, K; Konishi, O; Maruyama, H; Odawara, T; Toya, S, 2021) |
| " Chronic administration of L-DOPA plus ZNS in PD model mice was shown to increase the duration and severity of LID compared with PD model mice that were treated with L-DOPA alone." | 1.51 | The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice. ( Nambu, A; Sano, H, 2019) |
| " Chronic administration of zonisamide in Engrailed mutant mice was shown to improve the survival of nigrostriatal dopaminergic neurons compared with that under saline treatment." | 1.42 | Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease. ( Murata, M; Nambu, A; Sano, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, K | 2 |
| Kochi, K | 1 |
| Maruyama, H | 1 |
| Konishi, O | 1 |
| Toya, S | 1 |
| Odawara, T | 3 |
| Kajiwara, R | 1 |
| Takeuchi, H | 1 |
| Tagawa, M | 1 |
| Kosaka, K | 1 |
| Murata, M | 2 |
| Hinkle, JT | 1 |
| Pontone, GM | 1 |
| Hershey, LA | 1 |
| Irwin, DJ | 1 |
| Sano, H | 2 |
| Nambu, A | 2 |
| Shiozaki, K | 1 |
| Togo, T | 1 |
| Hirayasu, Y | 1 |
| Yokoyama, H | 2 |
| Yano, R | 2 |
| Kuroiwa, H | 2 |
| Tsukada, T | 2 |
| Uchida, H | 2 |
| Kato, H | 2 |
| Kasahara, J | 2 |
| Araki, T | 2 |
| Choudhury, ME | 1 |
| Moritoyo, T | 1 |
| Yabe, H | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Kubo, M | 1 |
| Matsuda, S | 1 |
| Nomoto, M | 1 |
2 trials available for zonisamide and Parkinsonian Disorders
| Article | Year |
|---|---|
Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.
Topics: Aged; Anticonvulsants; Double-Blind Method; Female; Humans; Japan; Lewy Body Disease; Male; Neuropsy | 2021 |
Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.
Topics: Double-Blind Method; Humans; Lewy Body Disease; Outpatients; Parkinsonian Disorders; Treatment Outco | 2022 |
8 other studies available for zonisamide and Parkinsonian Disorders
| Article | Year |
|---|---|
Invited Perspective on the "Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial".
Topics: Double-Blind Method; Humans; Lewy Body Disease; Parkinsonian Disorders; Zonisamide | 2022 |
Zonisamide for DLB parkinsonism: An old drug used in a new context.
Topics: Double-Blind Method; Humans; Levodopa; Lewy Body Disease; Parkinsonian Disorders; Zonisamide | 2018 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopam | 2019 |
Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Brain-Derived Neurotrophic Factor; Dopaminergic | 2015 |
Administration of zonisamide in three cases of dementia with Lewy bodies.
Topics: Aged; Antiparkinson Agents; Caregivers; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
Zonisamide attenuates MPTP neurotoxicity in marmosets.
Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dopamine; Female; Humans; Isoxazoles; Ma | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |